Nanoscope Therapeutics to Present Key Updates on Vision-Restoring Therapies at AAO 2025

Nanoscope Therapeutics to Present Key Updates on Vision-Restoring Therapies at AAO 2025

Dallas, TX – The inherited retinal disease (IRD) community is buzzing with anticipation as Nanoscope Therapeutics Inc., a biotechnology company focused on novel therapies for photoreceptor loss, has announced multiple presentations at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting. These presentations will highlight their proprietary Multi-Characteristic Opsin (MCO) platform, particularly its lead candidate, MCO-010, which aims to restore vision for patients with severe vision loss from conditions like retinitis pigmentosa (RP) and Stargardt disease.

For individuals and families affected by IRDs, these updates represent significant progress in the quest for effective treatments. Many IRDs, including RP and Stargardt disease, currently lack approved therapies, making every development in this field critically important.

Nanoscope Therapeutics is slated to present at the AAO 2025 Annual Meeting, scheduled for October 18-20, 2025, in Orlando, FL, and also at Eyecelerator@AAO 2025 on October 16, 2025.

Key presentations will include:

• **